Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

HIV/AIDS

Researchers from the People's Republic of China, United States and Sweden provide details of new studies and findings in the area of HIV/AIDS

Study 1: Intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120 elicited neutralizing antibodies.

Investigators in China report, "Recombinant viral vectors are useful tools for AIDS vaccine development. However, expression of HIV-1 envelope genes using viral vectors has not been successful in the induction of potent neutralizing antibodies in vivo. We took advantage of the strong immunogenicity of vesicular stomatitis virus (VSV)-based vector and expressed HIV-1 HXB2 gp120 gene in...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications